Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Urine test could guide heart failure treatment and save lives

NCT ID NCT07558798

Disease control Sponsor: University Hospital, Akershus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adjusting diuretic doses based on urine sodium levels improves outcomes for people hospitalized with acute heart failure and severe fluid buildup. About 270 participants will be randomly assigned to either standard care or a strategy where diuretic doses are doubled if urine sodium is low. The goal is to see if this approach reduces deaths, hospital readmissions, and length of stay.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
loop diuretics (e.g., furosemide)
What this could lead to
If successful, this approach could reduce deaths, hospital readmissions, and hospital stays for people with severe heart failure.
What could go wrong
This is a relatively small, early-stage study (270 participants) that has not yet started. The benefit may be modest or not apply to all patients, and the urine-sodium monitoring adds complexity to care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 270 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18 years * Hospitalization with AHF, either de novo or worsening of chronic HF * Able to provide written informed consent * Requirement of intravenous loop diuretic treatment as judged by the treating physician Exclusion Criteria: * Dyspnea primarily due to non-cardiac causes * Advanced renal disease or estimated glomerular filtration rate (eGFR) \< 20 mL/min/1.73m2 at screening or on-going dialysis. * Enrollment in another study interfering with the treatment algorithm of the current study * Inability to follow the treatment protocol * Language barriers requiring the need for an external interpreter * Pregnant or nursing (lactating) women * Very short life expectancy (\<30 days)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diuretics are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure Hyperemia VEXAS syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diuretics Heart failure, acute Venous congestion VEXUS

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Akershus University Hospital

    Lørenskog, Akershus, 1478, Norway

  • Østfold Hospital Trust

    Sarpsborg, Østfold fylke, 1714, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.